Medicenna Therapeutics Corp Cash Flow Conversion Efficiency

Latest as of December 2025: -0.799x

Medicenna Therapeutics Corp cash flow conversion efficiency. Based on the latest financial reports, Medicenna Therapeutics Corp (MDNA) has a cash flow conversion efficiency ratio of -0.799x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-4.96 Million ≈ $-3.59 Million USD) by net assets (CA$6.21 Million ≈ $4.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Medicenna Therapeutics Corp (2014–2025)

Cash flow conversion efficiency of Medicenna Therapeutics Corp from 2014 to 2025. This chart illustrates how Medicenna Therapeutics Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Medicenna Therapeutics Corp stock quote for real-time trading data and today's change.

Medicenna Therapeutics Corp Cash Flow Conversion Ratio Explained

Medicenna Therapeutics Corp cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Medicenna Therapeutics Corp Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Medicenna Therapeutics Corp ranked by their cash flow conversion efficiency. Also see Medicenna Therapeutics Corp market capitalisation for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
HI SPAC 3 KQ:217500	-0.025x
Hoftex Group AG MU:NBH	0.032x
Bookook Steel KO:026940	-0.006x
Hedef Girisim Sermayesi IS:HDFGS	-0.162x
Australis Oil & Gas Ltd AU:ATS	0.083x
THE INX DIGITAL CO.INC. F:FN4	N/A
DocGo Inc NASDAQ:DCGO	-0.042x
Ulima Nitra PT JK:UNIQ	0.040x

Annual Cash Flow Conversion Efficiency for Medicenna Therapeutics Corp (2014–2025)

The table below shows the annual cash flow conversion efficiency of Medicenna Therapeutics Corp from 2014 to 2025. Review Medicenna Therapeutics Corp (MDNA) financial flexibility to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-03-31	CA$19.09 Million ≈ $13.81 Million	CA$-16.49 Million ≈ $-11.93 Million	-0.864x	+72.43%
2024-03-31	CA$5.19 Million ≈ $3.76 Million	CA$-16.26 Million ≈ $-11.76 Million	-3.132x	-629.72%
2023-03-31	CA$29.49 Million ≈ $21.33 Million	CA$-12.66 Million ≈ $-9.16 Million	-0.429x	+62.08%
2022-03-31	CA$20.84 Million ≈ $15.07 Million	CA$-23.58 Million ≈ $-17.06 Million	-1.132x	-182.01%
2021-03-31	CA$38.15 Million ≈ $27.59 Million	CA$-15.31 Million ≈ $-11.08 Million	-0.401x	-62.04%
2020-03-31	CA$36.15 Million ≈ $26.15 Million	CA$-8.95 Million ≈ $-6.48 Million	-0.248x	+91.94%
2019-03-31	CA$2.62 Million ≈ $1.89 Million	CA$-8.04 Million ≈ $-5.81 Million	-3.072x	+34.41%
2018-03-31	CA$2.16 Million ≈ $1.56 Million	CA$-10.12 Million ≈ $-7.32 Million	-4.683x	-326.75%
2017-03-31	CA$6.66 Million ≈ $4.82 Million	CA$-7.31 Million ≈ $-5.28 Million	-1.097x	+4.17%
2016-03-31	CA$2.24 Million ≈ $1.62 Million	CA$-2.57 Million ≈ $-1.86 Million	-1.145x	-102.51%
2015-03-31	CA$-19.30K ≈ $-13.96K	CA$-880.32K ≈ $-636.81K	45.603x	+1865.98%
2014-03-31	CA$-267.05K ≈ $-193.18K	CA$-619.44K ≈ $-448.09K	2.320x	--

About Medicenna Therapeutics Corp

TO:MDNA Canada Biotechnology

Market Cap

$25.04 Million

CA$34.62 Million CAD

Market Cap Rank

#24202 Global

#905 in Canada

Share Price

CA$0.42

Change (1 day)

-2.35%

52-Week Range

CA$0.35 - CA$1.64

All Time High

CA$7.00